V
29.05
-2.15 (-6.89%)
| Previous Close | 31.20 |
| Open | 30.99 |
| Volume | 2,544,833 |
| Avg. Volume (3M) | 2,173,643 |
| Market Cap | 2,093,439,872 |
| Price / Book | 5.84 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2026 |
| Diluted EPS (TTM) | -3.00 |
| Total Debt/Equity (MRQ) | 10.18% |
| Current Ratio (MRQ) | 27.68 |
| Operating Cash Flow (TTM) | -155.26 M |
| Levered Free Cash Flow (TTM) | -97.14 M |
| Return on Assets (TTM) | -23.46% |
| Return on Equity (TTM) | -39.49% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Vera Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 5.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -4.0 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.32 |
Select this tab to load the latest available analysis.
|
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 3.97% |
| % Held by Institutions | 112.39% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |